Targeting HPV-related cancers with engineered T cells
E7 TCR-T cell therapy for HPV-associated cancers
This study is testing a new treatment for HPV-related cancers, like cervical and anal cancers, by using your own immune cells to better fight the cancer while protecting healthy tissue, and it's aimed at helping patients with tough-to-treat cases.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10827717 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for cancers associated with human papillomavirus (HPV), such as cervical and anal cancers. It utilizes a type of immunotherapy that involves engineering a patient's own T cells to specifically target and attack cancer cells expressing the HPV E7 protein. By using high-avidity T cells, the therapy aims to enhance the immune response against these tumors while minimizing damage to healthy tissues. The approach has shown promise in early clinical trials for patients with advanced-stage, treatment-resistant cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced-stage HPV-associated cancers who have not responded to standard treatments.
Not a fit: Patients with non-HPV-associated cancers or those who are in early stages of HPV-related cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and targeted treatment option for patients suffering from HPV-associated cancers.
How similar studies have performed: Similar approaches using engineered T cell therapies have shown success in other cancer types, indicating potential for this novel treatment in HPV-associated malignancies.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Hinrichs, Christian — Rutgers Biomedical and Health Sciences
- Study coordinator: Hinrichs, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.